SOLUBLE TREM-1 AS A MARKER OF SEVERITY OR COMPLICATIONS FOR A SUBJECT SUFFERING FROM A CORONAVIRUS INFECTION

The present invention relates to the use of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) as a marker in a method for identifying a subject suffering from a disease caused by a coronavirus such as COVID-19 at risk of having or developing a severe form and/or a complication or at...

Full description

Saved in:
Bibliographic Details
Main Authors GARAUD, Jean-Jacques, JOLLY, Lucie, GIBOT, Sébastien, MOULIN, David, DE NOOIJER, Aline, SALCEDO-MAGGUILLI, Margarita, NETEA, Mihai, DERIVE, Marc
Format Patent
LanguageEnglish
French
Published 09.12.2021
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present invention relates to the use of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) as a marker in a method for identifying a subject suffering from a disease caused by a coronavirus such as COVID-19 at risk of having or developing a severe form and/or a complication or at risk of death, in a method for assessing the severity of a disease caused by a coronavirus such as COVID-19, and in a method for monitoring a subject suffering from a disease caused by a coronavirus such as COVID-19. La présente invention concerne l'utilisation d'un récepteur de déclenchement soluble exprimé sur les cellules myéloïdes 1 (sTREM-1) utilisé comme marqueur dans un procédé d'identification d'un sujet souffrant d'une maladie provoquée par un coronavirus telle que la COVID-19 ayant un risque de présenter ou de développer une forme grave et/ou une complication ou un risque de décès, dans un procédé d'évaluation de la gravité d'une maladie provoquée par un coronavirus telle que la COVID-19, et dans un procédé de surveillance d'un sujet souffrant d'une maladie provoquée par un coronavirus telle que la COVID-19.
Bibliography:Application Number: WO2021EP65196